Whole Genome Sequencing Data
Buy and sell whole genome sequencing data data. Complete DNA sequences — the raw material for precision medicine AI. One genome is a novelty; 10,000 is a goldmine.
No listings currently in the marketplace for Whole Genome Sequencing Data.
Find Me This Data →Overview
What Is Whole Genome Sequencing Data?
Whole Genome Sequencing (WGS) data represents the complete DNA sequences of individuals—the raw material for precision medicine, drug discovery, and genetic research. A single genome provides limited utility, but aggregated datasets of thousands or millions of sequences enable AI systems to identify disease patterns, predict treatment responses, and drive breakthrough discoveries in personalized medicine. The market reflects this exponential value proposition: global WGS market was valued at US$2.1 billion in 2024 and is projected to reach US$5.8 billion by 2030, growing at 19% annually. WGS data is used across clinical diagnostics, reproductive health screening, infectious disease tracking, agricultural genomics, and cutting-edge precision medicine applications powered by machine learning.
Market Data
US$2.1 Billion
Global WGS Market 2024
Source: Research and Markets
US$5.8 Billion
Projected Market 2030
Source: Research and Markets
19% CAGR (2024–2030)
Market Growth Rate
Source: Research and Markets
USD 16.75 Billion
Broader DNA Sequencing Market 2024
Source: SkyQuest
500,000 individuals
UK Biobank Sequenced Participants
Source: The Medical Futurist
Who Uses This Data
What AI models do with it.do with it.
Precision Medicine & Drug Development
Pharmaceutical companies and biotech firms use WGS data to identify genetic variants linked to disease susceptibility, optimize drug efficacy prediction, and develop targeted therapies tailored to specific patient populations.
Clinical Diagnostics & Reproductive Health
Healthcare providers leverage WGS for prenatal screening, genetic disease diagnosis, and patient stratification to enable personalized treatment pathways and improve clinical outcomes.
Infectious Disease Research & Public Health
Genomic data enables rapid tracking of pathogen evolution, variant surveillance during disease outbreaks, and epidemiological research to support disease control strategies.
Agricultural Genomics
Breeding programs and agricultural biotech companies use WGS for crop improvement and animal breeding to increase yield and disease resistance.
What Can You Earn?
What it's worth.worth.
Individual Genome Sequences
Varies
Pricing depends on dataset size, quality, phenotype richness, and buyer exclusivity requirements. Single genomes have minimal commercial value; datasets of 1,000+ sequences command premium pricing.
Curated Cohorts (Disease-Specific)
Varies
Datasets with detailed clinical phenotypes, family history, and treatment outcomes attract higher valuations from pharmaceutical and precision medicine researchers.
Population-Scale Datasets
Varies
Large-scale datasets (10,000+ individuals) with demographic diversity and longitudinal health records represent significant institutional value for machine learning and population health studies.
What Buyers Expect
What makes it valuable.valuable.
Sequence Depth & Accuracy
Buyers require high-quality sequencing with adequate coverage and minimal errors, often 30x or greater depth for clinical reliability. Sequencing technology (NGS, third-generation) and quality metrics must be documented.
Data Privacy & Compliance
Genomic data is highly sensitive. Datasets must comply with HIPAA, GDPR, and other regulatory frameworks. Informed consent documentation, de-identification protocols, and ethical review board approval are essential to mitigate legal and reputational risk.
Clinical & Phenotypic Metadata
Raw sequences are more valuable when paired with clinical annotations—disease diagnosis, treatment records, lab results, and family history. Structured, standardized metadata increases utility for machine learning applications.
Sample Provenance & Reproducibility
Buyers expect clear documentation of sample collection, storage, processing protocols, and batch information. Standardized workflows and traceability reduce analytical noise and improve reproducibility across studies.
Companies Active Here
Who's buying.buying.
Leading DNA sequencing technology provider; drives WGS adoption through instrument innovation and pricing reduction, enabling broader market access.
Collaborated in 2024 to develop AI-augmented whole-genome sequencing applications with increased speed and clinical accuracy, representing enterprise-scale genomic analysis platforms.
Cancer genomics startup; developed automated workflow for implementing WGS data in oncology, targeting precision oncology market with AI-driven variant interpretation.
Large-scale biobank that has sequenced 500,000 participants; operates as a research resource providing WGS data access to academic and commercial researchers.
Population health initiative aiming to gather genetic data from one million individuals; represents major institutional aggregator of diverse, longitudinal WGS datasets.
FAQ
Common questions.questions.
What is the difference between one genome and a dataset of 10,000 genomes in commercial value?
A single genome has novelty value only; it lacks statistical power for population-level insights or disease association studies. Datasets of 10,000+ genomes enable machine learning systems to identify robust genetic patterns, disease biomarkers, and treatment predictors—unlocking commercial applications in drug development, precision medicine, and biomarker discovery.
Why has WGS market growth accelerated to 19% CAGR?
Sequencing costs have fallen dramatically, AI and big data analytics have matured to unlock genomic insights, and clinical adoption has expanded across precision medicine, prenatal screening, and infectious disease tracking. Partnerships between public institutions and private healthcare organizations have also facilitated broader genomic data access.
What are the main barriers to selling WGS data?
Data privacy and ethical concerns are critical. Genomic information is highly sensitive, raising questions about consent, data ownership, and potential misuse. Regulatory frameworks governing genetic testing vary by region. Buyers also expect high-quality sequences paired with robust clinical metadata and documented compliance with HIPAA, GDPR, and institutional review board standards.
Who are the primary buyers of WGS datasets?
Major buyers include pharmaceutical and biotech companies (drug discovery and clinical trials), academic research institutions and biobanks, healthcare systems (precision medicine and diagnostics), agricultural genomics firms, and public health agencies tracking infectious disease. Companies like Illumina, AI-genomics platforms (Sophia Genetics, NVIDIA, Microsoft), and large cohort initiatives (UK Biobank, All of Us) are leading market participants.
Sell yourwhole genome sequencingdata.
If your company generates whole genome sequencing data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation